The Myeloma Landscape in Australia and New Zealand (ANZ): The First Eight Years of the Myeloma and Related Diseases Registry (MRDR)

Abstract: Background Real-world multiple myeloma (MM) data are scarce, with most data originating from clinical trials. The MRDR is a prospective, clinical quality registry of newly diagnosed cases of plasma cell disorders, established in 2012 operating at 44 sites in ANZ as of April 2020. Methods We reviewed all patients enrolled onto the MRDR between June 2012 and April 2020. Baseline characteristics, treatment, and outcome data were reviewed for MM patients with comparisons made using chi-square tests (categorical variables) and rank sum tests (continuous variables). Kaplan-Meier analysis was used to estimate PFS/OS. Results As of April, 2020, 2405 MM patients were enrolled (median age 67y, 40% \u003e70y). High-risk features were present in 13-31% of patients: FISH [≥1 of t(4;14), t(14;16) or del17p] 18%, ISS-3 31% or R-ISS-3 13%. Cytogenetics/FISH were performed in 50% and 68% of patients, respectively, with an abnormal karyotype in 34%. Bortezomib-containing therapy was the most common first-line therapy (79.3%, n=1706). Patients not receiving bortezomib were older (median age 76y versus 65y, p Conclusion Clinical registries provide a more complete picture of MM diagnosis and treatment and highlight the challenges of adhering to ‘best practice’ in a real-world context.